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Background: We hypothesized that the combination of bevacizumab, 
carboplatin, and pemetrexed will be an effective first-line regimen in 
fit, elderly patients with nonsquamous non–small-cell lung cancer .
Methods: Treatment-naïve, stage IIIB/IV nonsquamous non–small-
cell lung cancer patients more than 70 years old with good perfor-
mance status (Eastern Cooperative Oncology Group performance 
status 0–1) and adequate organ function were eligible. Carboplatin 
area under the curve 6, pemetrexed 500 mg/m2, and bevacizumab 
15 mg/kg were administered on day 1 of each 21-day cycle (up to 
six cycles) followed by maintenance pemetrexed and bevacizumab. 
The primary end point of 6-month progression-free survival rate of 
at least 70% was assessed using a one-stage binomial design. Quality 
of life (QOL) questionnaires were administered. Polymorphisms in 
genes encoding relevant proteins (drug targets, transport, and metab-
olism proteins) were correlated with treatment outcome.
Results: Fifty-seven eligible patients were enrolled. Median age was 
74.5 years. Median treatment cycles received was 6. The most com-
mon grade 3 or higher non-hematologic adverse events were fatigue 
(26%) and hypertension (11%); 16% had grade 4 neutropenia and 
6.5% had grade 4 thrombocytopenia. Three patients experienced 
grade 3/4 hemorrhagic events (one pulmonary, two gastrointestinal). 
Primary end point of PFS6 was 60% (95% confidence interval [CI]: 
45.9–73%). Median PFS was 7.0 months (95% CI: 5.9–10.1), median 
overall survival was 13.7 months (95% CI: 9.4–16.8). Polymorphic 
KDR and VEGFA variants correlated with survival and toxicity, 
respectively. There was no significant change in overall QOL scores 
over time.
Conclusion: This regimen is feasible and did not decrease the QOL 
in this study population. However, it did not meet the primary effi-
cacy end point.
Key Words: Non-small cell lung cancer, Elderly, Nonsquamous his-
tology, Bevacizumab, Survival
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The phase III ECOG4599 study demonstrated the relevance of angiogenesis as a therapeutic target in metastatic non–
small-cell lung cancer (NSCLC) by showing that addition of 
bevacizumab to first-line carboplatin and paclitaxel (CbPac) 
improved survival.1 However, subsequent analysis showed 
that patients older than 70 years in the bevacizumab arm had 
more frequent and severe toxicities and did not have better 
progression-free survival (PFS) or overall survival (OS).2 One 
hypothesis is that the baseline toxicity of the CbPac backbone 
in elderly patients could contribute to this finding.
Pemetrexed is a multitargeted anti-folate that is indi-
cated for NSCLC patients with nonsquamous histology.3–5 A 
phase II single-arm study of carboplatin, pemetrexed, beva-
cizumab (CbPemBev)as front-line therapy for advanced 
nonsquamous NSCLC showed promising efficacy (overall 
response rate [ORR] of 55%, PFS of 7.8 months, and OS 
of 14 months).6 Because of the favorable safety profile in a 
general population, N0821 was designed to evaluate the effi-
cacy and tolerability of CbPemBev specifically in good PS 
patients greater than or equal to 70 years old using the same 
regimen described by Patel et al.6 Gene polymorphisms in 
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the folate and angiogenesis pathways are associated with 
variations in treatment outcomes.7–15 We therefore tested 
for an association of clinical outcomes with variations 
in eight pathway genes associated with pemetrexed and 
bevacizumab.
METHODS
Patients and Treatment
Eligible patients were greater than or equal to 70 years 
old with Eastern Cooperative Oncology Group performance 
status 0–1, chemonaive stage IIIB (malignant pleural effusion) 
or IV nonsquamous NSCLC (TNM 6th edition) with measur-
able disease as defined by Response Evaluation Criteria in Solid 
Tumors(1.0) and adequate bone marrow (hemoglobin ≥ 9 g/dl; 
absolute neutrophil count ≥ 1500/ul; platelet count ≥ 100,000/
ul), hepatic (total bilirubin ≤ 1.5× upper limit of normal or direct 
bilirubin < upper limit of normal; aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) ≤ 3× upper limit of 
normal or ≤ 5× upper limit of normal in the presence of hepatic 
metastases), and renal function (creatinine clearance ≥ 45 ml/
min). Patients with treated and asymptomatic brain metastases 
were allowed to participate. Exclusions include uncontrolled 
hypertension, acute cardiovascular events within 6 months of 
registration, history of abdominal fistulas, gastrointestinal per-
foration or intra-abdominal perforations within the preceding 12 
months, active hemoptysis more than 2.5 ml per event, concur-
rent use of anticoagulants and presence of serious or non-healing 
ulcers, wounds, or bone fractures. Central review of pathologic 
diagnosis was mandatory. NSCLC tumors were classified as 
adenocarcinoma, squamous cell carcinoma, carcinoma not oth-
erwise specified based on H&E structure and available immu-
nohistochemistry. Patients with a NSCLC diagnosis other than 
squamous cell carcinoma subtype were deemed eligible.
This single-arm, multicenter phase II study consisted of 
two treatment phases. In the induction phase, patients were 
treated with up to six cycles of carboplatin (AUC6), peme-
trexed (500 mg/m2), and bevacizumab (15 mg/kg) adminis-
tered on day 1 of a 21-day cycle. In the maintenance phase, 
patients without progression were eligible to continue peme-
trexed (500 mg/m2) and bevacizumab (15 mg/kg) administered 
on day 1 of a 21-day cycle until progression or intolerance. 
All patients received standard of care vitamin supplementa-
tion and dexamethasone premedication. Restaging computed 
tomography (CT) scans were obtained after each two cycles of 
therapy. Patients who had disease progression or undue toxic-
ity, refused further treatment or were deemed by their treating 
physicians to be more suitably treated with alternative meth-
ods at any treatment phase were taken off study treatment and 
monitored for adverse events (AE) and survival.
Quality of Life (QOL) Assessment
QOL was assessed using the Lung Cancer Symptom 
Scale (LCSS) and the single-item Linear Analogue Self 
Assessment (LASA) questionaires. A treatment-specific AEs 
scale consisting of one item each for fatigue, neuropathy and 
nausea was also administered. QOL was assessed at baseline, 
before cycle 3 and before cycle 5.
Pharmacogenetic Studies
Patient DNA samples were analyzed for polymorphisms 
in genes encoding proteins that affect pemetrexed metabolism 
or efficacy (FPGS, GGH, SLC19A1, and TYMS) and in genes 
that represent key mediators of the VEGF signaling pathway 
(VEFGA), FLT1 (VEGFR1), KDR (VEGFR2), and FLT4 
(VEGFR3). Acquisition of tagSNPs and genotyping were as 
previously described.7
Statistical Analyses
The primary end point of this single stage phase II 
study was the 6-month PFS (PFS6). A one-stage binomial 
design with an exact two-sided significance level of 0.05 and 
power of 93% was used to test the hypothesis that the true 
success rate (eligible patient who started treatment and is 
progression free at 6 months) was at most 50% versus the 
alternative hypothesis that the true success rate was at least 
70%. The null and alternate rates for the primary end point 
were derived based on an exponential survival model from 
the 95% confidence interval (CI) for the median PFS reported 
in the Patel phase et al.6 II study, which was 5.2–11.5 months. 
With a sample size of 55 evaluable patients, the regimen 
would be declared promising if at least 34 successes were 
observed. Secondary end points included AE profile, con-
firmed response rates (RR), PFS, and OS.
OS was defined as the time from registration to death 
because of any cause. PFS was defined as the time from reg-
istration to the first date of disease progression or death as a 
result of any cause. PFS was censored at the date of the last 
contact for patients alive and progression free at the time of 
this analysis. Exact binomial CIs for the proportion of suc-
cesses were constructed. The distribution of PFS and OS time 
was estimated using the Kaplan-Meier (KM) method.16
QOL scores were translated onto a 0–100 point scale 
with higher values indicating worse symptoms,17 and sum-
marized descriptively at each time point. Changes from base-
line in overall and individual item QOL scores were analyzed 
using a paired sample t-test.
Patient genotypes were correlated in an exploratory anal-
ysis with primary (PFS6) and secondary (AE, RR, PFS, and 
OS) endpoints. Logistic regression models were used to com-
pare the PFS6 status, AE patterns, and ORR between the differ-
ent tagged single nucleotide polymorphism (SNP)  subgroups. 
KM curves were used to visually compare the OS and PFS 
distributions between the different tagged SNP subgroups, and 
Cox regression models were used to assess the impact of the 
genotype subgroups on OS and PFS. No adjustments for mul-
tiple comparisons were performed in this exploratory exercise.
Each participant signed an IRB-approved, protocol-spe-
cific informed consent in accordance with federal and institu-
tional guidelines. Data collection and statistical analyses were 
conducted by the Alliance Statistics and Data Center.
RESULTS
This protocol was activated on December 12, 2008, and 
permanently closed to patient accrual on October 1, 2010, 
after accruing 65 patients. Final analysis as of November 6, 
2012, is reported. Figure 1 shows the CONSORT diagram of 
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the study enrollment. Three patients who never received any 
study treatment are excluded from all analyses. Table 1 sum-
marizes the demographic and baseline characteristics of the 62 
patients who received treatment on this study and follow-up 
information. One patient was still receiving active treatment 
at the time of data lock. Median number of cycles received by 
all 62 patients treated was six (range 1–43). Median number 
of cycles of the triplet combination received by all 62 patients 
treated was six (range 1–6). Twenty-eight patients received a 
median of four cycles of pemetrexed and bevacizumab only 
(range 1–37). Twenty-four patients received at least one dose 
reduction, most often to manage a non-hematologic AE (63% 
of all dose modifications between the three agents). Median 
follow-up for the 15 living patients is 25.4 months (range, 
1.1–37.4 months). All 62 patients who received treatment are 
included in the AE summary. Five patients who were deemed 
ineligible are excluded from all efficacy analysis. The patient 
cohorts evaluable for the different endpoints are described in 
the CONSORT diagram.
Primary End Point
Of the 55 patients evaluable for PFS, 33 were progression 
free at 6 months, resulting in 60% PFS6 (95% CI 45.9–73%). 
Two patients were lost to follow-up before 6 months and were 
considered as failures for the PFS6 end point. Thus, the trial 
did not meet the primary end point of at least 70% PFS6. A 
Kaplan-Meier estimate (considering the two lost to follow-up 
patients as censored observations) of the PFS6 for the first 55 
evaluable patients yields 64.2% (95% CI 49.7–75.5%).
Secondary Efficacy Outcomes
Of 55 patients evaluable for tumor response, 28 had a 
partial or complete response for an ORR of 50.9% (95% CI 
37.1–64.7%). Confirmed RR was seen in 22 patients (40%, 
95% CI 27.0–54.1%), one of whom had a complete response. 
Median PFS was 7 months (95% CI 5.9–10.7) and median 
OS was 13.7 months (95% CI 9.4–16.8) for a 1-year survival 
estimate of 57% (42.6–69.0%). Figures 2 and 3 show the KM 
curves for PFS and OS, respectively for all 57 eligible patients.
AE Profile
All 62 patients are evaluable for AEs. Table 2 summarizes 
the observed toxicities. Grade 3 or higher AE were reported 
in 54 (87%) patients. There were no treatment-related deaths. 
The grade 3 non-hematologic AEs occurring in at least 10% 
of patients were fatigue (26%) and hypertension (11%). The 
grade 3 hematologic AEs occurring in at least 10% of patients 
were neutropenia (29%) and thrombocytopenia (18%). Grade 
3 or higher anemia occurred in 4.8%. Grade 3 or higher hem-
orrhages occurred in 5%. One patient had neutropenic fever 
and developed typhlitis during his hospitalization. Twenty 
two (36%) patients ended study treatment because of AEs 
(however, additional data on specific AEs were not collected). 
Of the 22 patients, eight discontinued treatment during the 
65
62
3 Patients never received 
any study treatment, 
excluded from all analysis
57
5 Patients Ineligible, 
excluded from efficacy 
analysis*
Demographics
Follow-up
Adverse Events
Overall Survival
Progression-Free Survival
Pharmacogenetic analysis**
*Three patients with incorrect histology; One radiotherapy within 2 weeks of study; One patient 
had moderate pleural effusion that was not drained prior to therapy as required by the protocol; 
** Not all 57 patients had results for each genotype 
2 Patients with 
missing or 
incomplete 
QOL
2 Patients with no 
post-baseline 
disease 
assessments
First 55 patients 
evaluable for primary 
endpoint per protocol
55 evaluable for 
QOL
55 evaluable for 
Response Rate
FIGURE 1.  CONSORT diagram.
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maintenance phase whereas the remaining 14 patients ended 
study within the first six cycles of treatment. Twenty-nine 
patients had at least one dose delay implemented during their 
course of therapy.
QOL Analysis
At baseline, the median scores for all individual ques-
tions were greater than 50, with a summated LCSS score 
of 72.2 (inter-quartile range [IQR]: 58.9–84.4) and overall 
LASA score of 70 (IQR: 50–90). Although there was a sta-
tistically significant worsening in the pain QOL domain of 
LCSS, the overall QOL as evaluated by the LASA or the LCSS 
did not show any significant change over time. The median 
(IQR) baseline neuropathy, nausea, and fatigue were respec-
tively 100.0 (IQR: 90–100), 100.0 (IQR: 90–100), and 60.0 
(IQR: 40–70), where higher values indicate worse symptoms. 
Although there were no significant changes in the fatigue or 
neuropathy as assessed by the single item questions, a statisti-
cally significant improvement from baseline was observed for 
nausea at cycle 3 (mean score: 94.36 versus 87.33; p = 0.0142) 
and cycle 5 assessment (mean score: 94.36 versus 85.41; 
p = 0.0191). Figure 4 shows the temporal changes for various 
QOL measures.
Pharmacogenetic Analysis
Sixty-four tagSNPs generated from the eight genes with 
minor allele frequency greater than 5% were successfully gen-
otyped. Most of the SNPs genotyped were in Hardy-Weinberg 
equilibrium, supplementary Table 1, SDC 1, http://links.lww.
com/JTO/A606. Genotypes observed in less than five patients 
were regrouped and if the regrouped frequency was less than 
or equal to 10%, the SNP was excluded from the analyses 
with the clinical outcomes. SNPs that were not in Hardy-
Weinberg equilibrium were also excluded from analysis with 
clinical outcomes. Several of the SNPs genotyped were asso-
ciated significantly with the clinical outcomes at p less than 
0.05 (supplementary Tables 2–4, SDC 1, http://links.lww.
com/JTO/A606). For example, in KDR (VEGFR2) rs7671745 
polymorphism, the AG+AA genotypes, compared with the 
homozygous GG genotype, were associated with superior 
confirmed RR (odds ratio [OR] = 4, 95% CI 1.11–14.47, 
p = 0.029) and PFS6 (OR = 4.062, 95% CI 1.29–12.78, 
p = 0.014). For the VEGFA rs3025018 polymorphism, CG+GG 
genotypes compared with the homozygous CC genotype were 
TABLE 1.  Patient Demographics and Follow-Up
Total (N = 62)
Age (years)
  Median 74.5
  Range (70–86)
Gender
  Female 31 (50.0%)
ECOG performance status
  0 30 (48.4%)
  1 32 (51.6%)
Race
  White 58 (93.5%)
  Black or African-American 2 (3.2%)
  Unknown 2 (3.2%)
Histologic type
  Adenocarcinoma 44 (71.0%)
  Othera 18 (29.0%)
NSCLC stage (TNM 6th edition)
  Stage IIIB 9 (14.5%)
  Stage IV 53 (85.5%)
Follow-up time (months) in alive patients
  N 15
  Median 25.4
  Range (1.1–37.4)
Cycles of therapy given
  N 527
  Median 6.0
  Range (1–43)
Patients off study 61 (98.4%)
N
Reason ended treatment
  Refused further treatment 10 (16.4%)
  Adverse event 22 (36.1%)
  Disease progression 27 (44.3%)
  Otherb 2 (3.3%)
aThis table includes the three patients who were eventually deemed ineligible 
because of incorrect histology upon central review (see CONSORT diagram).
b One patient because of lack of insurance coverage; 1 MD discretion.
NSCLC, non–small-cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
FIGURE 2.  Kaplan-Meier curve for progression-free survival.
FIGURE 3.  Kaplan-Meier curve for overall survival.
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associated with inferior PFS (hazard ratio = 6.9, 95% CI = 
2.21–21.3, p = 0.0001) and OS (hazard ratio = 6.8, 95% CI 
= 2.14–21.53, p = 0.0002). The CT+TT genotypes in VEGFA 
rs3025035 polymorphism, compared with the homozygous 
CC genotype, were associated with reduced toxicity specifi-
cally grade 3+ AEs (OR = 0.152, 95% CI = 0.026–0.880, p = 
0.0209) and grade 3+ non-hematologic AEs (OR = 0.158, 95% 
CI = 0.032–0.776, p = 0.0137). In addition, there was a signifi-
cant association with reduced toxicity for TYMS rs2847153 
G>A (OR = 0.244, 95% CI = 0.071–0.847, p = 0.0218) and 
GGH rs3780130 A>T (OR = 0.181, 95% CI = 0.035–0.923, 
p = 0.0277) polymorphisms, whereas the AA genotype for 
SLC19A1 rs2838958 was associated with inferior confirmed 
response compared with the GG genotype (p = 0.0312).
DISCUSSION
Bearing in mind the usual caveats about cross-trial com-
parisons, the toxicities and OS end point seen in this study 
were overall comparable with those reported by Spigel et al 
in a randomized phase II study of a similar elderly patient 
population treated in the carboplatin, pemetrexed, and beva-
cizumab arm.18 Of note, there are some differences in the 
regimen utilized in the Spigel study. The carboplatin dose was 
slightly lower (area under the curve [AUC] 5 in contrast to 
AUC of 6 utilized in our study) and its maintenance phase 
utilized bevacizumab alone (pemetrexed was combined with 
bevacizumab during maintenance in our study). In compari-
son with another phase II study of a similar elderly patient 
population treated with six cycles of carboplatin AUC 5 with 
pemetrexed 500 mg/m2 followed by observation (no mainte-
nance phase), the outcomes with median ORR of 29%, PFS 
of 5.5 months, OS of 10.4 months, and 1-year OS rate of 
42%, appeared to be somewhat inferior to results seen in our 
study.19In the phase II Patel et al.6 study wherein the median 
age of patients treated was 63.5 years (range 34–80.5), the 
median PFS of 7.8 months, OS 14.1 months, PFS6 rate of 
59%, and 1-year OS rate of 61% were comparable as well to 
what was observed in our cohort of geriatric patients with a 
median age of 74.5 years (7 months, 13.7 months, 60% and 
57%, respectively). However, in contrast to the toxicity rates 
described in the phase II Patel et al.6 study, our patient popu-
lation generally encountered higher rates of grade greater 
than or equal to three AEs (e.g., neutropenia, thrombocyto-
penia, hemorrhage, and fatigue). This is not unexpected, in 
retrospect, as a subsequent dose-escalation study of carbo-
platin and pemetrexed (with a subsequent maintenance peme-
trexed phase) in 17 Japanese patients greater than or equal to 
75 years observed dose-limiting myelosuppression (grade 4 
thrombocytopenia and grade 3 febrile neutropenia) in three 
of seven patients treated at carboplatin AUC 6, leading to the 
recommended dose of carboplatin AUC 5 in combination with 
pemetrexed 500 mg/m2 in the elderly.20
Our efficacy data were also consistent with the results 
seen among patients randomized to this treatment regimen in 
the recently reported phase III POINTBREAK study (34.1% 
and 12.6 months) where it was compared with carboplatin, 
paclitaxel, and bevacizumab.21 The safety results from this 
phase III study showed that the side effect profile may favor 
the pemetrexed combination over the paclitaxel combination 
in terms of lower rates of grade 3/4 neutropenia (25.8% versus 
40.6%), febrile neutropenia (1.4% versus 4.1%), and sensory 
neuropathy (0% versus 4.1%). However, fatigue (5% versus 
TABLE 2.  Adverse Events (AEs)
Adverse Event  
(Max Grade per Event)
No. of Patients  
(Total = 62) %
Patients with at least one 
of the following:
  Grade 3/4/5 AE 54 87.1
  Grade 4/5 AE 21 33.9
  Grade 3/4 hematologic 
AE
33 53.2
  Grade 4 hematologic 
AE
13 21.0
  Grade 3/4/5 
nonhematologic AE
45 72.6
  Grade 4/5 
nonhematologic AE
10 16.1
All grade 4 hematologic 
AEs
  Anemia 1 1.6
  Lymphocytopenia 1 1.6
  Neutropenia 10 16.1
  Thrombocytopenia 4 6.5
  Leukopenia 1 1.6
All grade 4 
nonhematologic AEs
  Abdominal pain 1 1.6
  Dyspnea 1 1.6
  Fracture 1 1.6
  Hypertension 1 1.6
  Myocardial ischemia 1 1.6
  Thrombosis 1 1.6
  Ventricular tachycardia 1 1.6
  Lower gastrointestinal 
hemorrhage
1 1.6
  Sepsis 1 1.6
All grade 5 
nonhematologic AEs
  Disease progression 2 3.2
Grade 3 or higher AEs 
occurring in ≥10% of 
Patients
  Fatigue 16 25.8
  Hypertension 7 11.3
  Neutropenia 18 29.0
  Thrombocytopenia 11 17.7
Grade 3 or higher 
anemia/hemorrhage
  Anemia 3 4.8
  Pulmonary 
hemorrhage
1 1.6
  Lower gastrointestinal 
hemorrhage
1 1.6
  Jejunal hemorrhage 1 1.6
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10.9%) and thrombocytopenia (5.6% versus 23.3%) rates 
were higher with the pemetrexed combination, such that study 
discontinuations because of AEs or serious AEs and drug-
related deaths were similar between the two treatment arms.21 
Subgroup efficacy analyses in patients greater than 70 years 
show OS and PFS results consistent with the intention-to-treat 
population. In a pooled exploratory analysis based on age 
in the phase III E4599 and POINTBREAK studies, patients 
greater than or equal to 75 years who received bevacizumab 
in combination with carboplatin and paclitaxel had a higher 
incidence of grade 3 AEs relative to carboplatin and paclitaxel 
alone with no statistically significant survival benefit.22 Despite 
the grade 3+ fatigue documented in more than a quarter of our 
patients, the fatigue domain of LCSS and single-item LASA in 
fact indicated less fatigue reported by patients who remained 
on study at the time of cycle 3, although this change was not 
statistically significant. Our QOL data suggest that there is no 
worsening of patient QOL scores over time when this regimen 
is used as first-line treatment for a geriatric population.
The benefit of combining bevacizumab with carbopla-
tin and pemetrexed compared with the platinum/pemetrexed 
combination as first-line therapy can only be speculated as 
there are no phase III data addressing this question. In three 
phase II and one phase III predominantly non-Asian studies 
of carboplatin pemetrexed in younger populations and includ-
ing some squamous histologies, grade 3/4 neutropenia ranged 
between 10.3% and 33%, objective RRs ranged between 
22% and 34%, median time to progression/PFS were 5.4 to 6 
months, median OS was 10.3 to 14.9 months, and 1-year OS 
ranged from 43.9% to 56%.23–26 Whether the benefit:risk ratio 
favors incorporating bevacizumab into the carboplatin/peme-
trexed regimen for well-selected fit elderly patients is yet to be 
demonstrated. Although maintenance pemetrexed is thought 
to be nonstandard in elderly patients, our study demonstrates 
the feasibility of this approach as nearly half of our patients 
received maintenance treatment, with a median for four cycles 
administered. Pemetrexed should thus be offered to eligible 
patients with advanced nonsquamous NSCLC and good PS, 
regardless of age, based on the known survival benefit of this 
approach compared with placebo.27
Although prognostic and predictive associations of 
VEGFA and VEGFR polymorphic variants have been reported 
in NSCLC and other tumor types,8–11,28–34 some of these 
reports have conflicted in part because of the heterogeneity 
of patient populations and treatment regimens across studies. 
In this study, the variant alleles of bevacizumab-associated 
genes such as VEGFA SNP rs3025018 was significantly asso-
ciated with both inferior PFS and OS and rs3025035 with 
reduced toxicity, although KDR (VEGFR2) SNP rs1870377 
was associated with inferior PFS6. Furthermore, the peme-
trexed related gene SLC19A1 rs2838958 SNP, which showed 
reduced association with confirmed RR is linked to SLC19A1 
rs1051298 SNP (r2 = 0.8) which correlated previously with 
inferior survival.7 Finally, TYMS, the target for pemetrexed 
and 5FU, contained SNP rs2847153 which correlated with 
toxicity in this study and which had been reported previously 
to be associated with 5FU cytotoxicity.35
In conclusion, bevacizumab in combination with car-
boplatin-pemetrexed as first-line therapy in nonsquamous 
NSCLC patients greater than or equal to 70 years was well tol-
erated and was associated with an encouraging PFS rate, but 
did not meet the specified efficacy end point of this phase 2 
trial. Several candidate SNPs may have prognostic and predic-
tive implications for treatment outcomes using this regimen 
and may be explored in future studies. This study however 
was limited by lack of a control group and lack of available 
information regarding molecular subtypes of tumors among 
patients enrolled. Future clinical trials should incorporate this 
data into study design and analytical tools refined to account 
for such variations or missing information.
FIGURE 4.  Median and standard errors of 
the quality of life scores by time point.
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